Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Operating Leases (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Operating Leases data on record, last reported at $180000.0 in Q3 2025.

  • For Q3 2025, Operating Leases changed N/A year-over-year to $180000.0; the TTM value through Sep 2025 reached $180000.0, changed N/A, while the annual FY2024 figure was $218000.0, 15.18% down from the prior year.
  • Operating Leases reached $180000.0 in Q3 2025 per ZBIO's latest filing, down from $215000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $317000.0 in Q1 2025 and bottomed at $180000.0 in Q3 2025.
  • Average Operating Leases over 3 years is $237400.0, with a median of $218000.0 recorded in 2024.
  • The widest YoY moves for Operating Leases: up 15.18% in 2024, down 15.18% in 2024.
  • A 3-year view of Operating Leases shows it stood at $257000.0 in 2023, then fell by 15.18% to $218000.0 in 2024, then decreased by 17.43% to $180000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $180000.0 in Q3 2025, $215000.0 in Q2 2025, and $317000.0 in Q1 2025.